The oncoprotein gankyrin binds to MDM2/HDM2, enhancing ubiquitylation and degradation of p53

被引:191
作者
Higashitsuji, H
Higashitsuji, H
Itoh, K
Sakurai, T
Nagao, T
Sumitomo, H
Masuda, T
Dawson, S
Shimada, Y
Mayer, RJ
Fujita, J
机构
[1] Kyoto Univ, Grad Sch Med, Dept Clin Mol Biol, Sakyo Ku, Kyoto 6068507, Japan
[2] Univ Nottingham, Sch Med, Queens Med Ctr, Sch Biomed Sci,Lab Intracellular Proteolysis, Nottingham NG7 2UH, England
[3] Kyoto Univ, Grad Sch Med, Dept Surg & Surg Basic Sci, Sakyo Ku, Kyoto 6068507, Japan
基金
英国生物技术与生命科学研究理事会;
关键词
D O I
10.1016/j.ccr.2005.06.006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Gankyrin is an ankyrin repeat oncoprotein commonly overexpressed in hepatocellular carcinomas. Gankyrin interacts with the S6 proteasomal ATPase and accelerates the degradation of the tumor suppressor Rb. We show here that gankyrin has an antiapoptotic activity in cells exposed to DNA damaging agents. Downregulation of gankyrin induces apoptosis in cells with wild-type p53. In vitro and in vivo experiments revealed that gankyrin binds to Mdm2, facilitating p53-Mdm2 binding, and increases ubiquitylation and degradation of p53. Gankyrin also enhances Mdm2 autoubiquitylation in the absence of p53. Downregulation of gankyrin reduced amounts of Mdm2 and p53 associated with the 26S proteasome. Thus, gankyrin is a cofactor that increases the activities of Mdm2 on p53 and probably targets polyubiquitylated p53 into the 26S proteasome.
引用
收藏
页码:75 / 87
页数:13
相关论文
共 49 条
[1]   Regulation of p53 and MDM2 activity by MTBP [J].
Brady, M ;
Vlatkovic, N ;
Boyd, MT .
MOLECULAR AND CELLULAR BIOLOGY, 2005, 25 (02) :545-553
[2]   A post-ubiquitination role for MDM2 and hHR23A in the p53 degradation pathway [J].
Brignone, C ;
Bradley, KE ;
Kisselev, AF ;
Grossman, SR .
ONCOGENE, 2004, 23 (23) :4121-4129
[3]   Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation [J].
Brooks, CL ;
Gu, W .
CURRENT OPINION IN CELL BIOLOGY, 2003, 15 (02) :164-171
[4]   Inhibiting the p53-MDM2 interaction:: An important target for cancer therapy [J].
Chène, P .
NATURE REVIEWS CANCER, 2003, 3 (02) :102-109
[5]  
Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO
[6]  
2-Q
[7]   Gankyrin is an ankyrin-repeat oncoprotein that interacts with CDK4 kinase and the S6 ATPase of the 26 S proteasome [J].
Dawson, S ;
Apcher, S ;
Mee, M ;
Higashitsuji, H ;
Baker, R ;
Uhle, S ;
Dubiel, W ;
Fujita, J ;
Mayer, RJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (13) :10893-10902
[8]   The ubiquitin ligase COP1 is a critical negative regulator of p53 [J].
Dornan, D ;
Wertz, I ;
Shimizu, H ;
Arnott, D ;
Frantz, GD ;
Dowd, P ;
O' Rourke, K ;
Koeppen, H ;
Dixit, VM .
NATURE, 2004, 429 (6987) :86-92
[9]   THE MDM-2 ONCOGENE CAN OVERCOME WILD-TYPE P53 SUPPRESSION OF TRANSFORMED-CELL GROWTH [J].
FINLAY, CA .
MOLECULAR AND CELLULAR BIOLOGY, 1993, 13 (01) :301-306
[10]   Control of apoptosis by p53 [J].
Fridman, JS ;
Lowe, SW .
ONCOGENE, 2003, 22 (56) :9030-9040